dr. tyna moore glp-1 Personalized GLP-1s for Body, Brain & Metabolic Health Interview with Dr. Tyna Moore,

Frost G, Brynes A, Leeds A

Some patients prefer daily dosing because it becomes part of their morning routine, but this is the minority

A patient in a medically supervised program can receive guidance on protein targets, exercise strategy, dose tolerance, hydration, digestion, lab markers, and adjunctive therapies when appropriate

We hypothesised that the metabolite GLP-1(936) (previously believed to be biologically inactive) exerts a direct inhibitory effect on glucagon secretion and that this mechanism becomes impaired in diabetes

The medication is already in liquid form, the dose mechanism is built in, and the process requires minimal preparation